Price Chart
Key Statistics
Market Cap(EOD)47.90M
Enterprise Value-547,800
P/E Ratio (TTM)-0.83
P/B Ratio (TTM)0.89
P/S Ratio (TTM)1.27
Earnings Yield (TTM)-120.61%
ROE (TTM)-81.80%
ROIC (TTM)-110.07%
Net Profit Margin (TTM)N/A
Dividend Yield (TTM)N/A
Payout Ratio (TTM)N/A
Debt/Equity (TTM)0.04
About Shattuck Labs, Inc.
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.